• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZONG Yungang. Analysis and suggestions on the development trend of drug innovation in China[J]. Journal of China Pharmaceutical University, 2023, 54(3): 380-388. DOI: 10.11665/j.issn.1000-5048.20220906001
Citation: ZONG Yungang. Analysis and suggestions on the development trend of drug innovation in China[J]. Journal of China Pharmaceutical University, 2023, 54(3): 380-388. DOI: 10.11665/j.issn.1000-5048.20220906001
shu

Analysis and suggestions on the development trend of drug innovation in China

  • National Medical Products Administration Institute of Medical Economics, Guangzhou 510140, China

More Information
  • Received Date: September 05, 2022
  • Revised Date: May 05, 2023
    Graphical Abstract
    • Abstract
  • In order to comprehensivehy evaluate the stage of China in the global drug innovation, to further optimize the environment for drug innovation in China, and to unleash the vitality of drug innovation, this article mainly analyzes through comparison China''s situation of drug innovation in global competition from such perspectives as the current situation of the global drug R&D innovation market, R&D investment, product pipeline, policy support, and development trends, combined with the characteristics of China''s drug innovation development.It can be seen that China''s pharmaceutical innovation is faced with such practical problems as lagging behind some developed countries in terms of innovation development, companies bunching into research and development innovation, sudden research and development rush, and excessive dependence on capital markets for pharmaceutical innovation.Accordingly, this paper puts forward suggestions on continuously improving China''s new drug innovation environment, rationally selecting differentiated competition and new tracks, reasonably formulating drug innovation development strategies, guiding capital to return to innovative research and development, and constructing a "double cycle" strategy for drug innovation.
    • FullText(HTML)
    • References (14)
  • [1]
    Lloyd I.Pharma R&D Annual Review 2020[EB/OL].(2020-07-18)[2021-09-12]. https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2020/files/whitepapers/rd-review-2020-whitepaper-update.pdf.
    [2]
    Li R, Meng J, Zhao RC, et al. Analysis of research and development status of new drugs in 2022[J]. Chin Bull Life Sci (生命科学), 2023, 35(1): 80-87.
    [3]
    Frost & Sullivan. China CRO Industry Market Research Report.[EB/OL][2020-06-19].https://www.frostchina.com/content/insight/detail?id=62f366d357d0761f000a3433.
    [4]
    BDO. Revenue, R&D and biotech''s future[EB/OL]. [2021-12-20]. https://www.bdo.com/BDO/media/Misc-Documents/LS_Biotech-Brief-Report_Summer-2021_WEB.pdf.
    [5]
    Deloitte. Seeds of change: measuring the return from pharmaceutical innovation 2020[EB/OL]. (2021-07-20)[2021-12-20]. https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life-sciences-health-care /deloitte-uk-measuring-the-return-from-pharmaceutical-innovation-2021.pdf.
    [6]
    Chen J, Dong Z. Influence and countermeasures and suggestions of medical outsourcing in China on the basis of drug registration system reform[J]. China Pharm (中国药业), 2018, 27(23): 70-73.
    [7]
    Wu X, Shao R. Current situation and analysis of venture capital of innovative medicine[J]. Chin J Pharm (中国医药工业杂志), 2020, 51(8): 1070-1079.
    [8]
    Fu P, Lu JJ, Sun SY. Discussion on prospect of pharmaceutical innovation market and development of CRO industry in 2020[J]. Tianjin Sci Technol (天津科技), 2020, 47(5): 94-96.
    [9]
    Yao W, Yan JZ, Shao R. A study on the evaluation criteria of medical insurance negotiation admittance for innovative drugs in typical countries and its enlightenment to China[J]. Chin J New Drugs (中国新药杂志), 2021, 30(12): 1057-1062.
    [10]
    Yin SQ, Zhang H, Liu YH. The effect of policy implementation and some relevant suggestions on the inclusion of innovative tumor drugs in the national reimbursement drug list[J]. Chin Health Econ (中国卫生经济), 2021, 40(1): 22-24.
    [11]
    IQVIA. Global trends in R&D: overview through 2020[EB/OL]. (2021-05-19)[2021-10-02]. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-trends-in-r-and-d.
    [12]
    China Pharmaceutical Innovation and Research Development Association (PhIRDA), R&D-Based Pharmaceutical Association Committee (RDPAC). Promoting simultaneous R&D, registration and review of innovative drugs, fostering pharmaceutical innovation system in China[J]. China Food Drug Administ Magaz (中国食品药品监管), 2022, 7(222): 4-13.
    [13]
    Chen H, Chen PX. The hidden worries of "assault R&D"[J].Bus Manage (企业管理), 2020, 5: 48-53.
    [14]
    Sun TY. China''s pharmaceutical innovation has entered the second tier globally[J].China Econ Week (中国经济周刊), 2022, 5: 62-64.
    • Related Articles

Catalog

    Get Citation
    PDF
    XML
    Article views (152) PDF downloads (377) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：415148

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return